Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 7, 2012

ActiveSite Wins $1.3M to Complete Preclinical Development of Oral Diabetic Macular Edema Drug

  • ActiveSite Pharmaceuticals has been awarded a competitively renewed Phase II SBIR grant of up to $1.3 million by the NIH’s National Eye Institute. It will fund continued preclinical development of its lead orally administered plasma kallikrein (PK) inhibitor for the treatment of diabetic macular edema (DME). ActiveSite says it will use the funds to carry out preclinical safety and toxicology studies required to file an IND application for the start of clinical trials.

    ActiveSitehas previously been awarded funding by the NIH and other sources for its DME program. “The National Eye Institute’s continuing support of ActiveSite’s research efforts to identify and develop a safe, small molecule approach to the treatment of DME has allowed this program to reach this important milestone,” remarks Sukanto Sinha, Ph.D., CEO. “This moves us closer to the goal of bringing this novel, first-in-class, patient-friendly pharmacological approach into the clinic.”

    There are currently no FDA-approved drugs for DME, and, unlike ActiveSite’s PK inhibitor, drug candidates already in late-stage clinical development are delivered intravitreally, the firm notes. Preclinical studies have demonstrated that ActiveSite’s lead PK inhibitor stops diabetes-induced leakage of fluid into the retina in clinically relevant rodent models when delivered systemically.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »